Glaukos Corp. (GKOS)
221.44
+1.46
(+0.66%)
USD |
NYSE |
Nov 06, 15:36
Glaukos Research and Development Expense (Annual) : 150.61M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 150.61M |
| December 31, 2024 | 136.42M |
| December 31, 2023 | 138.77M |
| December 31, 2022 | 123.27M |
| December 31, 2021 | 101.00M |
| December 31, 2020 | 85.39M |
| December 31, 2019 | 68.31M |
| Date | Value |
|---|---|
| December 31, 2018 | 49.68M |
| December 31, 2017 | 38.90M |
| December 31, 2016 | 29.22M |
| December 31, 2015 | 25.05M |
| December 31, 2014 | 19.20M |
| December 31, 2013 | 15.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Globus Medical, Inc. | 146.94M |
| Edwards Lifesciences Corp. | 1.079B |
| Becton, Dickinson & Co. | 988.00M |
| Merit Medical Systems, Inc. | 97.35M |
| Insulet Corp. | 301.10M |